Placental endothelin-converting enzyme-1 is decreased in preeclampsia.
Endothelial cells
Endothelin
Endothelin-converting enzyme 1(ECE-1)
Placenta
Preeclampsia
Trophoblast
Journal
Pregnancy hypertension
ISSN: 2210-7797
Titre abrégé: Pregnancy Hypertens
Pays: Netherlands
ID NLM: 101552483
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
05
08
2019
revised:
30
03
2020
accepted:
03
04
2020
pubmed:
12
4
2020
medline:
25
8
2020
entrez:
12
4
2020
Statut:
ppublish
Résumé
Endothelin-converting enzyme-1(ECE-1) is a key regulatory enzyme in the processing of endothelin-1 (ET-1). We quantified and localized ECE-1 in normal and preeclamptic placentas. Normal (n=6) and preeclamptic (n=6) placentas were serially sectioned for immunofluorescence (IF). Cell type specific markers identified endothelial, trophoblast, macrophage, smooth muscle, and fibroblast cells. Quantitative analyses were performed by western blot and ELISA. IF identified ECE-1 expression within the stroma and villous space. Cellular localization of ECE-1 was limited to endothelial membranes. There was significantly less ECE-1 in preeclamptic placentas, suggesting ECE-1 is important for proper regulation of ET-1 within the placenta.
Identifiants
pubmed: 32278308
pii: S2210-7789(20)30039-8
doi: 10.1016/j.preghy.2020.04.001
pmc: PMC7532811
mid: NIHMS1633161
pii:
doi:
Substances chimiques
Biomarkers
0
ECE1 protein, human
EC 3.4.24.71
Endothelin-Converting Enzymes
EC 3.4.24.71
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108-110Subventions
Organisme : NHLBI NIH HHS
ID : K08 HL150340
Pays : United States
Informations de copyright
Copyright © 2020 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Robert Blank has the following disclosures: Consulting: Novo-Nordisk, Travel Support: Amgen, Ownership: Abbott Labs, Abbvie, Amgen, Authorship royalties: UpToDate, Authorship Fees: McGraw-Hill, Editorial Stipend: Elsevier. All other authors have no disclosures to report.
Références
J Biol Chem. 1999 Nov 5;274(45):32469-77
pubmed: 10542292
J Cardiovasc Pharmacol. 1993;22 Suppl 8:S73-6
pubmed: 7510004
Hypertens Pregnancy. 2003;22(3):215-24
pubmed: 14572358
J Cardiovasc Pharmacol. 1993;22 Suppl 8:S53-6
pubmed: 7509998
Hypertension. 2020 Mar;75(3):877-884
pubmed: 31884859
Nature. 1988 Mar 31;332(6163):411-5
pubmed: 2451132
Am J Obstet Gynecol. 2005 Jul;193(1):234-40
pubmed: 16021085
Curr Vasc Pharmacol. 2013 Sep;11(5):594-605
pubmed: 24063378
Biochem J. 1995 Oct 15;311 ( Pt 2):657-65
pubmed: 7487910
J Soc Gynecol Investig. 2001 Jan-Feb;8(1):18-23
pubmed: 11223352
Arch Biochem Biophys. 1994 Jan;308(1):240-53
pubmed: 8311460
Placenta. 2000 Mar-Apr;21(2-3):226-33
pubmed: 10736246
J Histochem Cytochem. 1993 Apr;41(4):535-41
pubmed: 8450193
J Cardiovasc Pharmacol. 1993;22 Suppl 8:S144-8
pubmed: 7509927
Circulation. 1998 Jan 27;97(3):234-6
pubmed: 9462522
Hypertens Pregnancy. 2001;20(1):125-37
pubmed: 12044321
Proc Natl Acad Sci U S A. 1988 Sep;85(18):6964-7
pubmed: 3045827
Curr Opin Nephrol Hypertens. 2012 Mar;21(2):157-62
pubmed: 22257796
Br J Pharmacol. 1992 Nov;107(3):858-60
pubmed: 1472978
Cell. 1994 Aug 12;78(3):473-85
pubmed: 8062389
Exp Biol Med (Maywood). 2006 Jun;231(6):723-8
pubmed: 16740988
Biochem J. 1997 Dec 15;328 ( Pt 3):871-7
pubmed: 9396733
J Biol Chem. 2002 Nov 29;277(48):46355-63
pubmed: 12244060
Cell Mol Life Sci. 2011 Jan;68(2):195-203
pubmed: 20848158
Development. 1998 Mar;125(5):825-36
pubmed: 9449665